Evidence map›Paper›PMID 28030831›Full record

ArticleOncotarget2017

Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.

Takashi Murakami, Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Yong Zhang, Ming Zhao, Yukihiko Hiroshima, Scott D Nelson, Sarah M Dry, Yunfeng Li and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Recombinant AttenuatedCancers · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Tumor-targetingHeliyon · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Takashi MurakamiAntiCancer, Inc., San Diego, California, USA.
Kentaro IgarashiAntiCancer, Inc., San Diego, California, USA.
Kei KawaguchiAntiCancer, Inc., San Diego, California, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, California, USA.
Yong ZhangAntiCancer, Inc., San Diego, California, USA.
Ming ZhaoAntiCancer, Inc., San Diego, California, USA.
Yukihiko HiroshimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Scott D NelsonDepartment of Pathology, University of California Los Angeles, California, USA.
Sarah M DryDepartment of Pathology, University of California Los Angeles, California, USA.
Yunfeng LiDepartment of Pathology, University of California Los Angeles, California, USA.
Jane YanagawaDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Tara RussellDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Noah FedermanDepartment of Pediatrics and Department of Orthopaedics, David Geffen School of Medicine, Mattel Children's Hospital, UCLA's Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.
Arun SinghDivision of Hematology-Oncology, University of California, Los Angeles, California, USA.
Irmina ElliottDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Ryusei MatsuyamaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Takashi ChishimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Kuniya TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, California, USA.
University of California, Los Angeles · USAntiCancer (United States) · USYokohama City University · JPUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma occurs mostly in children and young adults, who are treated with multiple agents in combination with limb-salvage surgery. However, the overall 5-year survival rate for patients with recurrent or metastatic osteosarcoma is 20-30% which has not improved significantly over 30 years. Refractory patients would benefit from precise individualized therapy. We report here that a patient-derived osteosarcoma growing in a subcutaneous nude-mouse model was regressed by tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R, p<0.001 compared to untreated control). The osteosarcoma was only partially sensitive to the molecular-targeting drug sorafenib, which did not arrest its growth. S. typhimurium A1-R was significantly more effective than sorafenib (P <0.001). S. typhimurium grew in the treated tumors and caused extensive necrosis of the tumor tissue. These data show that S. typhimurium A1-R is powerful therapy for an osteosarcoma patient-derived xenograft model.

Indexed as

Drug Resistance, NeoplasmAdolescentAnimalsAntineoplastic AgentsBiological TherapyBone NeoplasmsHumansMaleMice, NudeMolecular Targeted TherapyNecrosisNiacinamideOsteosarcomaPhenylurea CompoundsProtein Kinase InhibitorsSalmonella typhimuriumAntineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsSorafenibnude mouseosteosarcomapatient-derived xenograftSalmonella typhimurium A1-Rtumor-targeting

Identifiers

PMID28030831
PMCPMC5352380
OpenAlexW2566871225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.